NO2524060T3 - - Google Patents

Info

Publication number
NO2524060T3
NO2524060T3 NO11732315A NO11732315A NO2524060T3 NO 2524060 T3 NO2524060 T3 NO 2524060T3 NO 11732315 A NO11732315 A NO 11732315A NO 11732315 A NO11732315 A NO 11732315A NO 2524060 T3 NO2524060 T3 NO 2524060T3
Authority
NO
Norway
Application number
NO11732315A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44305841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2524060(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2524060T3 publication Critical patent/NO2524060T3/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO11732315A 2010-01-11 2011-01-11 NO2524060T3 (US07794700-20100914-C00194.png)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29404810P 2010-01-11 2010-01-11
US31619310P 2010-03-22 2010-03-22
PCT/US2011/020832 WO2011085369A1 (en) 2010-01-11 2011-01-11 Assay for jc virus antibodies

Publications (1)

Publication Number Publication Date
NO2524060T3 true NO2524060T3 (US07794700-20100914-C00194.png) 2018-04-28

Family

ID=44305841

Family Applications (1)

Application Number Title Priority Date Filing Date
NO11732315A NO2524060T3 (US07794700-20100914-C00194.png) 2010-01-11 2011-01-11

Country Status (27)

Country Link
US (2) US9316641B2 (US07794700-20100914-C00194.png)
EP (3) EP3339865B9 (US07794700-20100914-C00194.png)
JP (2) JP5946218B2 (US07794700-20100914-C00194.png)
KR (1) KR101877576B1 (US07794700-20100914-C00194.png)
CN (1) CN102906278A (US07794700-20100914-C00194.png)
AU (1) AU2011203815B2 (US07794700-20100914-C00194.png)
BR (1) BR112012017014B1 (US07794700-20100914-C00194.png)
CA (1) CA2784137A1 (US07794700-20100914-C00194.png)
CY (2) CY1119972T1 (US07794700-20100914-C00194.png)
DK (2) DK3339865T5 (US07794700-20100914-C00194.png)
ES (2) ES2930469T3 (US07794700-20100914-C00194.png)
FI (1) FI3339865T5 (US07794700-20100914-C00194.png)
HK (1) HK1255318A1 (US07794700-20100914-C00194.png)
HR (2) HRP20221390T1 (US07794700-20100914-C00194.png)
HU (2) HUE036183T2 (US07794700-20100914-C00194.png)
IN (1) IN2012DN06139A (US07794700-20100914-C00194.png)
LT (2) LT2524060T (US07794700-20100914-C00194.png)
ME (1) ME03026B (US07794700-20100914-C00194.png)
MX (1) MX341991B (US07794700-20100914-C00194.png)
NO (1) NO2524060T3 (US07794700-20100914-C00194.png)
NZ (1) NZ600681A (US07794700-20100914-C00194.png)
PL (2) PL2524060T3 (US07794700-20100914-C00194.png)
PT (2) PT2524060T (US07794700-20100914-C00194.png)
RS (2) RS56977B1 (US07794700-20100914-C00194.png)
SG (2) SG10201500079YA (US07794700-20100914-C00194.png)
SI (2) SI2524060T1 (US07794700-20100914-C00194.png)
WO (1) WO2011085369A1 (US07794700-20100914-C00194.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3264094T (lt) 2005-04-04 2021-04-12 Biogen Ma Inc. Imuninio atsako į terapijos agentą įvertinimo būdai
US20070207141A1 (en) 2006-02-28 2007-09-06 Ivan Lieberburg Methods of treating inflammatory and autoimmune diseases with natalizumab
JP5504390B2 (ja) 2006-03-03 2014-05-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド ナタリズマブを用いて炎症性疾患及び自己免疫疾患を治療する方法
WO2011044553A1 (en) 2009-10-11 2011-04-14 Biogen Idec Ma Inc. Anti-vla-4 related assays
US11287423B2 (en) * 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
PL2524060T3 (pl) 2010-01-11 2018-05-30 Biogen Ma Inc. Test wykrywający przeciwciała przeciwko wirusowi jc
EP2715352B1 (en) * 2011-05-31 2019-04-24 Biogen MA Inc. Method of assessing risk of pml
WO2013087601A2 (en) * 2011-12-12 2013-06-20 Janssen Diagnostics Bvba Polyomavirus peptide sequences
CA2870593A1 (en) * 2012-04-16 2013-10-24 Board Of Regents, The University Of Texas System Detection of extracellular jcv micrornas
US9631243B2 (en) 2012-06-18 2017-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for identifying JC virus
EP3517545A1 (en) * 2012-12-31 2019-07-31 Neurimmune Holding AG Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
US9949671B2 (en) 2013-03-13 2018-04-24 Orthoaccel Technologies, Inc. Diagnostic mouthpieces
EP3004334A4 (en) 2013-05-28 2016-12-21 Biogen Ma Inc METHODS OF EVALUATION RISK OF DEVELOPMENT OF PML
EP3757224A3 (en) 2014-02-27 2021-03-17 Biogen MA Inc. Method of assessing risk of pml
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
IT201600083859A1 (it) * 2016-08-09 2018-02-09 Univ Degli Studi Di Ferrara Immunosaggio per l’identificazione di anticorpi contro il virus Polioma JC (JCPyV) mediante l’uso di peptidi sintetici.
US20210002372A1 (en) * 2018-03-02 2021-01-07 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating natalizumab-associated progressive multifocal encephalopathy

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4235601A (en) 1979-01-12 1980-11-25 Thyroid Diagnostics, Inc. Test device and method for its use
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US5763262A (en) 1986-09-18 1998-06-09 Quidel Corporation Immunodiagnostic device
DE3887771C5 (de) 1987-04-27 2009-06-04 Inverness Medical Switzerland Gmbh Immunoassays und Vorrichtungen dafür.
US4943522A (en) 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US4818677A (en) 1987-12-03 1989-04-04 Monoclonal Antibodies, Inc. Membrane assay using focused sample application
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5221616A (en) 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
US5118630A (en) 1988-11-04 1992-06-02 Quidel Corporation Method for determining periodic infertility in females
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5084828A (en) 1989-09-29 1992-01-28 Healthtech Services Corp. Interactive medication delivery system
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5096837A (en) 1990-02-08 1992-03-17 Pacific Biotech, Inc. Immunochromatographic assay and method of using same
US5223220A (en) 1990-03-27 1993-06-29 Pacific Biotech, Inc. Solid phase immunoassay device and method of making same
US5118428A (en) 1990-11-13 1992-06-02 Quidel Method to remove red blood cells from whole blood samples
DE4139840B4 (de) 1990-12-04 2005-06-02 Quidel Corp., San Diego Antigen-Zubereitung zum Nachweis von H. pylori
EP0566695B1 (en) 1991-01-11 1999-06-02 Quidel Corporation A one-step lateral flow assay and nonbibulous support used therein
US5213796A (en) 1991-05-06 1993-05-25 Dana Farber Cancer Institute Assay for polyomavirus in humans and uses thereof
US5225328A (en) 1991-05-30 1993-07-06 Quidel Corporation Stable alkaline phosphatase compositions with color enhancement and their use in assays
US5686315A (en) 1991-06-14 1997-11-11 Quidel Corporation Assay device for one step detection of analyte
JPH07503543A (ja) 1992-02-04 1995-04-13 クイデル　コーポレイション 乾燥試薬を用いる細菌抗原の簡易化抽出法
US5541069A (en) 1992-02-28 1996-07-30 Quidel Corporation Assay having improved dose response curve
ES2151902T3 (es) 1992-03-10 2001-01-16 Quidel Corp Medio de separacion de globulos rojos para dosificarlos mediante union especifica.
ATE182625T1 (de) 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
US5415994A (en) 1993-08-02 1995-05-16 Quidel Corporation Lateral flow medical diagnostic assay device with sample extraction means
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5434057A (en) 1994-02-02 1995-07-18 Quidel Corporation Sperm motility assay and devices
US5521102A (en) 1994-08-08 1996-05-28 Quidel Corporation Controlled sensitivity immunochromatographic assay
US5845255A (en) 1994-10-28 1998-12-01 Advanced Health Med-E-Systems Corporation Prescription management system
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US5712172A (en) 1995-05-18 1998-01-27 Wyntek Diagnostics, Inc. One step immunochromatographic device and method of use
US5804452A (en) 1995-04-27 1998-09-08 Quidel Corporation One step urine creatinine assays
US5786220A (en) 1995-04-28 1998-07-28 Quidel Corporation Assays and devices for distinguishing between normal and abnormal pregnancy
US20010051350A1 (en) 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
US5773234A (en) 1995-08-07 1998-06-30 Quidel Corporation Method and device for chlamydia detection
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
US6305377B1 (en) 1996-12-12 2001-10-23 Michael T. Portwood System and method for improving compliance of a medical regimen
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
US6306642B1 (en) 1997-11-24 2001-10-23 Quidel Corporation Enzyme substrate delivery and product registration in one step enzyme immunoassays
US6623981B2 (en) 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
US6014631A (en) 1998-04-02 2000-01-11 Merck-Medco Managed Care, Llc Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US7171371B2 (en) 1999-09-03 2007-01-30 Smg Trust Method and system for providing pre and post operative support and care
US7129053B1 (en) 1999-10-12 2006-10-31 Dakocytomation Denmark A/S Immuno-chromatographic rapid assay in order to detect acid-resistant microorganisms in the stool
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
EP1242118B1 (en) 1999-12-16 2009-11-11 Biogen Idec MA Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
EP1271152A4 (en) 2000-03-30 2005-04-27 Nippon Kayaku Kk METHOD FOR DETECTING CANCER BY MEASURING AUTOANTIC VIRUSES AGAINST MDM2 AND REAGENTS THEREFOR
US6620626B1 (en) 2000-08-09 2003-09-16 Mission Research Corp. Antigen detection device and method
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
WO2002033417A1 (en) 2000-10-17 2002-04-25 Besst-Test Aps Assay for directly detecting a rs virus related biological cell in a body fluid sample
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US6485460B2 (en) 2001-01-12 2002-11-26 Bracco Diagnostics, Inc. Tamper evident syringe barrel
WO2003016902A1 (en) 2001-08-20 2003-02-27 Proteome Systems Intellectual Property Pty Ltd Diagnostic testing process and apparatus
CA2457930C (en) * 2001-08-20 2012-06-19 Proteome Systems Intellectual Property Pty Ltd. Diagnostic testing process and apparatus
US6605602B1 (en) 2001-09-28 2003-08-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Method of treating BK virus nephropathy
AU2003213231A1 (en) 2002-02-25 2003-09-09 Elan Pharmaceuticals, Inc. Administration of agents for the treatment of inflammation
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
CA2490284C (en) 2002-06-21 2013-10-22 Mckesson Information Solutions Llc Closed loop medication use system and method
US20070275481A1 (en) 2003-11-24 2007-11-29 Biogen Idec Ma Inc. Methods For Detecting Half-Antibodies Using Chip Based Gel Electophoresis
JP4672263B2 (ja) 2004-01-27 2011-04-20 デンカ生研株式会社 簡便な検出法、検出装置及び検出キットとその製法
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US20050283385A1 (en) 2004-06-21 2005-12-22 The Permanente Medical Group, Inc. Individualized healthcare management system
NZ588839A (en) 2004-07-08 2012-09-28 Elan Pharm Inc Multivalent vla-4 antagonists comprising polyethylene glycol moieties
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CA2589379A1 (en) 2004-12-03 2006-06-08 Biogen Idec Ma Inc. Delaying or preventing onset of multiple sclerosis
ES2387317T3 (es) 2005-03-03 2012-09-20 Seedlings Life Science Ventures, Llc. Procedimiento de control de riesgos de pacientes en tratamiento con natalizumab
LT3264094T (lt) 2005-04-04 2021-04-12 Biogen Ma Inc. Imuninio atsako į terapijos agentą įvertinimo būdai
NZ567270A (en) 2005-09-29 2011-06-30 Elan Pharm Inc Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4
KR20080100271A (ko) 2006-02-27 2008-11-14 엘란 파마슈티칼스, 인크. Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제하는 피리미디닐 술폰아미드 화합물
US20070207141A1 (en) 2006-02-28 2007-09-06 Ivan Lieberburg Methods of treating inflammatory and autoimmune diseases with natalizumab
CA2641160A1 (en) 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
JP5504390B2 (ja) 2006-03-03 2014-05-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド ナタリズマブを用いて炎症性疾患及び自己免疫疾患を治療する方法
DE602007009446D1 (de) * 2006-06-30 2010-11-11 Sumitomo Rubber Ind Gummizusammensetzung für Reifenlauffläche und Reifen mit daraus hergestellter Reifenlauffläche
EP2089515A4 (en) 2006-11-16 2011-02-23 Novavax Inc VIRUSUAL PARTICLES OF RESPIRATORY SYNZYTIAL VIRUS
EP1933140B1 (en) 2006-12-11 2011-08-17 AraGen Biotechnology Co. Ltd. Antibody detection method involving an oligonucleotide enhanced collodial gold signal
NZ594973A (en) 2009-02-05 2012-05-25 Biogen Idec Inc Methods for the detection of JC polyomavirus and diagnosis of progressive multifocal leukoencephalopathy (PML)
WO2010096674A2 (en) 2009-02-20 2010-08-26 The Regents Of The University Of California A+ biomarker assays
PL2524060T3 (pl) * 2010-01-11 2018-05-30 Biogen Ma Inc. Test wykrywający przeciwciała przeciwko wirusowi jc
EP2715352B1 (en) 2011-05-31 2019-04-24 Biogen MA Inc. Method of assessing risk of pml

Also Published As

Publication number Publication date
HRP20180356T1 (hr) 2018-04-06
ES2930469T3 (es) 2022-12-14
EP3339865B1 (en) 2022-08-24
CY1126069T1 (el) 2023-11-15
RS56977B1 (sr) 2018-05-31
PL3339865T3 (pl) 2022-12-19
HK1255318A1 (zh) 2019-08-16
ME03026B (me) 2018-10-20
HUE060312T2 (hu) 2023-02-28
HRP20221390T1 (hr) 2023-01-06
EP2524060B1 (en) 2017-11-29
EP2524060A4 (en) 2013-10-09
PT2524060T (pt) 2018-03-28
LT3339865T (lt) 2022-12-12
SG10201500079YA (en) 2015-03-30
SI2524060T1 (en) 2018-05-31
CY1119972T1 (el) 2018-12-12
AU2011203815A1 (en) 2012-07-05
BR112012017014A2 (pt) 2016-04-05
RS63744B1 (sr) 2022-12-30
ES2664173T3 (es) 2018-04-18
HUE036183T2 (hu) 2018-06-28
US20160187337A1 (en) 2016-06-30
FI3339865T5 (fi) 2023-04-15
WO2011085369A1 (en) 2011-07-14
JP2013516633A (ja) 2013-05-13
KR20120112621A (ko) 2012-10-11
US20130022961A1 (en) 2013-01-24
CN102906278A (zh) 2013-01-30
EP3339865A1 (en) 2018-06-27
EP3339865B9 (en) 2022-12-14
US10444234B2 (en) 2019-10-15
DK3339865T5 (da) 2023-03-20
MX341991B (es) 2016-09-09
JP5946218B2 (ja) 2016-07-05
EP4152004A1 (en) 2023-03-22
KR101877576B1 (ko) 2018-07-12
SI3339865T1 (sl) 2023-01-31
DK2524060T3 (en) 2018-03-12
LT2524060T (lt) 2018-03-26
AU2011203815B2 (en) 2015-11-26
EP2524060A1 (en) 2012-11-21
MX2012007660A (es) 2012-07-25
PL2524060T3 (pl) 2018-05-30
BR112012017014B1 (pt) 2021-07-20
DK3339865T3 (da) 2022-11-28
PT3339865T (pt) 2022-11-22
US9316641B2 (en) 2016-04-19
CA2784137A1 (en) 2011-07-14
JP2016040557A (ja) 2016-03-24
SG181653A1 (en) 2012-07-30
FI3339865T3 (US07794700-20100914-C00194.png) 2022-11-30
NZ600681A (en) 2014-10-31
BR112012017014A8 (pt) 2018-06-05
IN2012DN06139A (US07794700-20100914-C00194.png) 2015-09-18

Similar Documents

Publication Publication Date Title
BR112013008959A2 (US07794700-20100914-C00194.png)
BR112012031500A2 (US07794700-20100914-C00194.png)
BR112012029986A2 (US07794700-20100914-C00194.png)
BR112012030039A2 (US07794700-20100914-C00194.png)
BR112012026492A2 (US07794700-20100914-C00194.png)
BR112012024897A2 (US07794700-20100914-C00194.png)
BR112012019354A2 (US07794700-20100914-C00194.png)
BR112012025307A2 (US07794700-20100914-C00194.png)
BR112012002126A2 (US07794700-20100914-C00194.png)
BR112012026946A2 (US07794700-20100914-C00194.png)
BR112012017960A2 (US07794700-20100914-C00194.png)
BR112012025482A2 (US07794700-20100914-C00194.png)
BR112013006400A2 (US07794700-20100914-C00194.png)
BR112012031826A2 (US07794700-20100914-C00194.png)
BR112012025577A2 (US07794700-20100914-C00194.png)
BR112012023249A2 (US07794700-20100914-C00194.png)
BR112012016456A2 (US07794700-20100914-C00194.png)
BR112012018256A2 (US07794700-20100914-C00194.png)
BR112012025308A2 (US07794700-20100914-C00194.png)
NO2524060T3 (US07794700-20100914-C00194.png)
BR112012024872A2 (US07794700-20100914-C00194.png)
BR112012023265A2 (US07794700-20100914-C00194.png)
BR112013010949A2 (US07794700-20100914-C00194.png)
BR112013003284A2 (US07794700-20100914-C00194.png)
BR112013002646A2 (US07794700-20100914-C00194.png)